• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Gridelli, Cesare
    Ardizzoni, Andrea
    Le Chevalier, Thierry
    Manegold, Christian
    Perrone, Francesco
    Thatcher, Nick
    Van Zandwijk, N
    Di Maio, Massimo
    Martelli, O
    De Marinis, F
    Affiliation
    Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy. cgridelli@libero.it
    Issue Date
    2004-03
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC), but its benefit seems limited to fit patients with a performance status (PS) of 0 or 1. For PS2 patients, there is no consensus on standard treatment. With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced NSCLC in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April 2003. RESULTS: and conclusions On the basis of current evidence, chemotherapy treatment appears justified for patients with advanced NSCLC and PS2. Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes) could be the preferred option, although carboplatin-based or low-dose cisplatin-based doublets may represent alternative options. Stronger evidence is expected from new clinical research specifically focused on PS2 patients. Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomised trials dedicated to PS2 patients. High priority should be given to the evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. Another research priority is the improvement of supportive care. Patients strongly need symptomatic improvement: end points such as symptom relief, clinical benefit and quality of life should have a central position in trials dedicated to PS2 NSCLC patients.
    Citation
    Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. 2004, 15 (3):419-26 Ann. Oncol.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/77735
    DOI
    10.1093/annonc/mdh087
    PubMed ID
    14998843
    Type
    Article
    Language
    en
    ISSN
    0923-7534
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdh087
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Chemotherapy of advanced NSCLC in special patient population.
    • Authors: Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del Gaizo F, Colantuoni G, Nicolella D, Napolitano L
    • Issue date: 2006 May
    • A systematic overview of chemotherapy effects in non-small cell lung cancer.
    • Authors: Sörenson S, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care
    • Issue date: 2001
    • Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
    • Authors: Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, Di Maio M, Langer C
    • Issue date: 2005 May 1
    • Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    • Authors: Plosker GL, Hurst M
    • Issue date: 2001
    • [Treatment of the unresectable non small cell lung carcinoma].
    • Authors: Spásová I
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.